Advertisement

Topics

Myovant’s Relugolix Combo Therapy Positive for Uterine Fibroids

20:00 EDT 13 May 2019 | BioSpace

Myovant Sciences announced positive data from LIBERTY 1, one of its two Phase III trials of once daily relugolix combination therapy in uterine fibroids. The trial met its primary endpoint and six key secondary endpoints.

Original Article: Myovant’s Relugolix Combo Therapy Positive for Uterine Fibroids

NEXT ARTICLE

More From BioPortfolio on "Myovant’s Relugolix Combo Therapy Positive for Uterine Fibroids"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topic

Clincial Trials
In a clinical trial or interventional study, participants receive specific interventions according to the research plan or protocol created by the investigators. These interventions may be medical products, such as drugs or devices; procedures; or change...